Literature DB >> 3717759

Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.

G R Sarma, C Immanuel, S Kailasam, A S Narayana, P Venkatesan.   

Abstract

The effect of daily administration of rifampin on the direct conversion of isoniazid to isonicotinic acid and hydrazine by isoniazid hydrolase was investigated in 6 slow and 8 rapid acetylators of isoniazid. The proportion of isoniazid metabolized through this direct pathway during the first 6 h was estimated from the ratio of total isonicotinic acid formed to acetylisoniazid in urine after administration of isoniazid or acetylisoniazid. In slow acetylators, this proportion was approximately 3% when isoniazid alone was administered and approximately 6% during the maximal phase of induction caused by the daily administration of rifampin in addition to isoniazid (p less than 0.001); in rapid acetylators, the proportions were considerably less (less than 1 and 2.5%, respectively), suggesting that isoniazid hydrolase was induced by rifampin. The increased formation of hydrazine, a known hepatotoxic agent in animals, could explain the substantially higher frequency of the occurrence of hepatitis in slow than in rapid acetylators among tuberculous patients treated with daily rifampin and isoniazid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3717759     DOI: 10.1164/arrd.1986.133.6.1072

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

Review 1.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 2.  Drug metabolism and hepatotoxicity.

Authors:  J M Tredger; M Davis
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

3.  Hepatobiliary quiz-6 (2013).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2013-06

4.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 6.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.

Authors:  Vidyasagar Ramappa; Guruprasad P Aithal
Journal:  J Clin Exp Hepatol       Date:  2012-12-20

7.  Hepatotoxicity caused by the combined action of isoniazid and rifampicin.

Authors:  D S Askgaard; T Wilcke; M Døssing
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

8.  A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases.

Authors:  Hoda A Makhlouf; Ahmed Helmy; Ehab Fawzy; Madiha El-Attar; Hebat Alla G Rashed
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

Review 9.  The pregnane X receptor in tuberculosis therapeutics.

Authors:  Amina I Shehu; Guangming Li; Wen Xie; Xiaochao Ma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-12-05       Impact factor: 4.481

Review 10.  Age-related changes in the manifestations of tuberculosis. Implications for drug therapy.

Authors:  S Umeki
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.